Download PDF
Der Klinikarzt 2019; 48(03): 78-81
DOI: 10.1055/a-0861-8564
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Embolischer Schlaganfall unbekannter Quelle (ESUS)

Hat sich das Konzept bewährt?
Ulf Ziemann
1   Abteilung Neurologie mit Schwerpunkt neurovaskuläre Erkrankungen, und Hertie-Institut für Klinische Hirnforschung, Eberhard-Karls-Universität Tübingen, Tübingen
› Author Affiliations
Further Information

Publication History

Publication Date:
01 April 2019 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

ESUS (embolischer Schlaganfall unbekannter Quelle) wurde als pathogenetisches Konzept mit der Erwartung entwickelt, dass eine orale Antikoagulation wirksamer als eine Thrombozytenfunktionshemmung einen erneuten Schlaganfall verhindern kann. Zwei pivotale Phase-III-Studien (NAVIGATE ESUS, RE-SPECT ESUS) haben diese Erwartung nicht bestätigt. ESUS ist keine singuläre pathogenetische Entität. Zukünftige Konzepte müssen das berücksichtigen, um einer personalisierten Therapie den Weg zu ebnen.

 

  • Literatur

  • 1 Adams Jr. HP, Bendixen BH, Kappelle LJ. et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41
    CrossrefPubMedGoogle Scholar
  • 2 Hart RG, Diener HC, Coutts SB. et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429-438
    CrossrefPubMedGoogle Scholar
  • 3 Hart RG, Catanese L, Perera KS. et al. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke 2017; 48: 867-872
    CrossrefPubMedGoogle Scholar
  • 4 European Stroke Organisation Executive C, Committee ESOW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507
    CrossrefPubMedGoogle Scholar
  • 5 Furie KL, Kasner SE, Adams RJ. et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 227-276
    CrossrefPubMedGoogle Scholar
  • 6 Cotter PE, Martin PJ, Ring L. et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology 2013; 80: 1546-1550
    CrossrefPubMedGoogle Scholar
  • 7 Ritter MA, Kochhauser S, Duning T. et al. Occult Atrial Fibrillation in Cryptogenic Stroke: Detection by 7-Day Electrocardiogram Versus Implantable Cardiac Monitors. Stroke 2013; 44: 1449-1452
    CrossrefPubMedGoogle Scholar
  • 8 Sanna T, Diener HC, Passman RS. et al. Cryptogenic stroke and underlying atrial fibrillation. New Engl J Med 2014; 370: 2478-2486
    CrossrefPubMedGoogle Scholar
  • 9 Poli S, Diedler J, Härtig F. et al. Insertable cardiac monitors after cryptogenic stroke – a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol 2016; 23: 375-381
    CrossrefPubMedGoogle Scholar
  • 10 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. Eur Stroke J 2016; 1: 146-154
    CrossrefPubMedGoogle Scholar
  • 11 Diener HC, Easton JD, Granger CB. et al. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke: official journal of the International Stroke Society 2015; 10: 1309-1312
    PubMedGoogle Scholar
  • 12 Geisler T, Poli S, Meisner C. et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. Int J Stroke 2017; 12: 985-990
    CrossrefPubMedGoogle Scholar
  • 13 Thijs VN, Brachmann J, Morillo CA. et al. Predictors for atrial fibrillation detection after cryptogenic stroke: Results from CRYSTAL AF. Neurology 2016; 86: 261-269
    CrossrefPubMedGoogle Scholar
  • 14 Hart RG, Sharma M, Mundl H. et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New Engl J Med 2018; 378: 2191-2201
    CrossrefPubMedGoogle Scholar
  • 15 Hankey GJ, Patel MR, Stevens SR. et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322
    CrossrefPubMedGoogle Scholar
  • 16 Verma N, Ziegler PD, Liu S. et al. Incidence of atrial fibrillation among patients with an embolic stroke of undetermined source: Insights from insertable cardiac monitors. Int J Stroke 2018 DOI: 10.1177/1747493018798554: 1747493018798554
    PubMedGoogle Scholar
  • 17 Kasner SE, Swaminathan B, Lavados P. et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol 2018; 17: 1053-1060
    CrossrefPubMedGoogle Scholar
  • 18 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-891
    CrossrefPubMedGoogle Scholar
  • 19 Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy recent – Data and ideas. Stroke 2005; 36: 1588-1593
    CrossrefPubMedGoogle Scholar
  • 20 Lip GYH, Keshishian A, Li X. et al. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. The ARISTOPHANES Study. Stroke 2018; 49: 2933-2944
    CrossrefPubMedGoogle Scholar
  • 21 Amarenco P, Albers GW, Denison H. et al. Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. Stroke 2017; 48: 2480-2487
    CrossrefPubMedGoogle Scholar
  • 22 Ntaios G, Papavasileiou V, Lip GY. et al. Embolic Stroke of Undetermined Source and Detection of Atrial Fibrillation on Follow-Up: How Much Causality Is There?. J Stroke Cerebrovasc Dis 2016; 25: 2975-2980
    CrossrefPubMedGoogle Scholar